New cocktail therapy aims to shrink Hard-to-Treat tumors
NCT ID NCT07327411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial will test a combination of four treatments—cetuximab β (a targeted antibody), radiation, an immunotherapy drug (envafolimab), and a growth factor (GM-CSF)—in 40 adults with advanced solid tumors that have EGFR protein and are no longer responding to standard care. The goal is to see if this mix can shrink tumors or slow disease progression. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cetuximab β (anti-EGFR antibody) combined with hypofractionated radiotherapy, envafolimab (PD-L1 inhibitor), and GM-CSF
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase trial (40 people) with no control group, so results may not apply broadly. The combination also carries risks of side effects from radiation and immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215163, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.